15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Bifunctional Peptide-Based Opioid Agonist-Nociceptin Antagonist Ligands for Dual Treatment of Acute and Neuropathic Pain.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Herein, the opioid pharmacophore H-Dmt-d-Arg-Aba-β-Ala-NH2 (7) was linked to peptide ligands for the nociceptin receptor. Combination of 7 and NOP ligands (e.g., H-Arg-Tyr-Tyr-Arg-Ile-Lys-NH2) led to binding affinities in the low nanomolar domain. In vitro, the hybrids behaved as agonists at the opioid receptors and antagonists at the nociceptin receptor. Intravenous administration of hybrid 13a (H-Dmt-d-Arg-Aba-β-Ala-Arg-Tyr-Tyr-Arg-Ile-Lys-NH2) to mice resulted in potent and long lasting antinociception in the tail-flick test, indicating that 13a was able to permeate the BBB. This was further supported by a cell-based BBB model. All hybrids alleviated allodynia and hyperalgesia in neuropathic pain models. Especially with respect to hyperalgesia, they showed to be more effective than the parent compounds. Hybrid 13a did not result in significant respiratory depression, in contrast to an equipotent analgesic dose of morphine. These hybrids hence represent a promising avenue toward analgesics for the dual treatment of acute and neuropathic pain.

          Related collections

          Author and article information

          Journal
          J. Med. Chem.
          Journal of medicinal chemistry
          American Chemical Society (ACS)
          1520-4804
          0022-2623
          Apr 28 2016
          : 59
          : 8
          Affiliations
          [1 ] Research Group of Organic Chemistry, Departments of Chemistry and Bio-engineering Sciences, Vrije Universiteit Brussel , Pleinlaan 2, 1050 Brussels, Belgium.
          [2 ] Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences , Smetna 12, PL 31-343 Kraków, Poland.
          [3 ] Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Réanimation Médicale et Toxicologique, Inserm U1144, Université Paris Descartes UMR-S 1144, Université Paris Didero, UMR-S 1144 , Paris, France.
          [4 ] Neuropeptide Laboratory, Medical Research Centre, Polish Academy of Sciences , 5 Pawinskiego Street, PL 02-106 Warsaw, Poland.
          [5 ] Department of Chemical Biology and Peptide Research, Clinical Research Institute , 110 Avenue Des Pins Ouest, Montreal, Quebec H2W 1R7, Canada.
          [6 ] University of Strasbourg, CNRS, UMR7242, ESBS , 67412 Illkirch-Graffenstaden, France.
          [7 ] Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST) , Baldiri Reixac 10, 08028 Barcelona, Spain.
          Article
          NIHMS779686
          10.1021/acs.jmedchem.5b01976
          4850106
          27035422
          9fe77294-9505-479f-b699-af0991467c57
          History

          Comments

          Comment on this article